LEGN Legend Biotech Corporation
USHealthcareAs of 2026-07-08 16:00
Why LEGN matters now
Legend Biotech Corporation (LEGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.87 with +0.69% on the session and $5.15B in market capitalization; recent performance reads 1-month +3.67% and YTD +28.47%.
The latest financial table shown here is Q1 2026, with revenue of $305.1M, net income of $-54.3M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.6%.
The latest indexable market news headline is "Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $64.50; recent insider activity includes Huang Ying filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.33
P/S
4.54
EV/EBITDA
-27.11
DCF Value
$-2,439.66
FCF Yield
-4.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
55.0%
Operating Margin
-11.9%
Net Margin
-22.0%
ROE
-24.9%
ROA
-15.7%
ROIC
-9.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $305.1M | $-54.3M | $-0.30 |
| Q4 2025 | $306.4M | $-30.8M | $-0.17 |
| FY 2025 | $1.03B | $-296.8M | $-1.60 |
| Q3 2025 | $272.3M | $-39.7M | $-0.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$58.00
Target (Median)
$64.50
Target Range
$24.00 - $75.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.35
Legend Biotech Corporation is a clinical-stage biopharmaceutical firm, operating through its various subsidiaries, dedicated to the discovery and advancement of innovative cell therapies. These treatments primarily target oncological conditions but also address other diseases across the United States, China, and international markets. The company's most advanced investigational therapy is LCAR-B38M, a chimeric antigen receptor (CAR) product specifically developed for treating multiple myeloma (MM). This lead candidate is currently undergoing comparative evaluation against standard triplet therapies in patients suffering from revlimid-refractory multiple myeloma. Additionally, Legend Biotech possesses a pipeline of early-stage, autologous product candidates, which are presently in Phase I clinical trials for addressing gastric cancer and T-cell lymphoma. The company is also actively developing CAR-T cell therapies designed to target CD20, CD22, and CD19 for the treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further expanding its therapeutic scope, the firm has product candidates in both early preclinical and clinical development phases aimed at solid tumors and infectious diseases. A significant collaboration exists with Janssen Biotech, Inc., for the joint development and commercialization of ciltacabtagene autoleucel. Founded in 2014, Legend Biotech Corporation is based in Somerset, New Jersey, and functions as a subsidiary of Genscript Biotech Corporation.